BSX logoBSX
Boston Scientific Corp.

6,407
Loading...
Loading...
News
all
press releases
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Boston Scientific (BSX) settling at $105.23, representing a -2.65% change from its previous close.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Reasons to Retain Avanos Medical Stock in Your Portfolio Now
AVNS's solid Q2 performance, strong product demand, and strategic transformation support growth amid tariff and FX headwinds.
Zacks·4d ago
News Placeholder
Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System
MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.
Zacks·5d ago
News Placeholder
Cardinal Health Expands At-Home Solutions With New Texas Facility
CAH announces the opening of a new distribution center in Texas, which is likely to support its at-Home Solutions business.
Zacks·6d ago
News Placeholder
GEHC Stock Gains Following Launch of Revolution Vibe CT Imaging System
GE HealthCare's FDA-cleared Revolution Vibe CT promises faster, AI-driven cardiac imaging with improved clarity, boosting efficiency and patient comfort.
Zacks·7d ago
News Placeholder
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq
PacBio collaborates with EpiCypher to integrate Fiber-Seq and HiFi sequencing, advancing single-molecule epigenomics with new chromatin mapping tools.
Zacks·9d ago
News Placeholder
Here's Why You Should Hold Cencora Stock in Your Portfolio Now
COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.
Zacks·10d ago
News Placeholder
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL's strong Q2 results, innovation pipeline, and high-tech growth drivers support its long-term expansion despite macro headwinds.
Zacks·10d ago
News Placeholder
HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y
HQY's Q2 results reflect EPS growth of 25.6% year over year, revenue growth of 8.6% and a 12% increase in HSA. The company also updates its fiscal 2026 guidance.
Zacks·11d ago
News Placeholder
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks·12d ago

Latest BSX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.